MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-12-2024
Psychemedics Corporation Retained Earnings 2011-2026 | PMD
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Psychemedics Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -16.8 M | -11.8 M | -9.55 M | -8.61 M | -3.75 M | -1.33 M | -2.11 M | -4.94 M | -8.3 M | -6.57 M | -6.56 M | -7.19 M | -7.01 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.33 M | -16.8 M | -7.27 M |
Quarterly Retained Earnings Psychemedics Corporation
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18.8 M | -18.3 M | -17.5 M | -16.8 M | -15.8 M | -13.7 M | -12.6 M | -11.8 M | -10.7 M | -10.2 M | -9.51 M | -9.55 M | -7.65 M | -8.39 M | -8.52 M | -8.61 M | -8.61 M | -8.61 M | -8.61 M | -3.75 M | -3.75 M | -3.75 M | -3.75 M | -1.33 M | -1.33 M | -1.33 M | -1.33 M | -2.11 M | -2.11 M | -2.11 M | -2.11 M | -4.94 M | -4.94 M | -4.94 M | -4.94 M | -8.3 M | -8.3 M | -8.3 M | -8.3 M | -6.57 M | -6.57 M | -6.57 M | -6.57 M | -6.56 M | -6.56 M | -6.56 M | -6.56 M | -7.19 M | -7.19 M | -7.19 M | -7.19 M | -7.01 M | -7.01 M | -7.01 M | -7.01 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.33 M | -18.8 M | -7.55 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
CareDx, Inc
CDNA
|
-735 M | $ 21.45 | 3.05 % | $ 1.14 B |  USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Agilent Technologies
A
|
348 M | $ 115.08 | -0.37 % | $ 35 B | USA |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 1.59 | 2.58 % | $ 2.12 M | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 24.93 | 1.8 % | $ 692 M | USA |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 14.45 | -4.87 % | $ 437 M | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M |  Israel |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 116.34 | -1.69 % | $ 9.6 B |  Irlanda |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 132.22 | 4.32 % | $ 21 B | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Lantheus Holdings
LNTH
|
680 M | $ 84.97 | 0.41 % | $ 5.73 B | USA |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 165.55 | -0.77 % | $ 8.21 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 419.03 | 0.09 % | $ 12.1 B | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 9.55 | 3.13 % | $ 1.22 B | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 17.05 | 3.58 % | $ 382 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 87.71 | 0.72 % | $ 11 B | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Personalis
PSNL
|
-550 M | $ 5.52 | - | $ 327 M | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.98 | 4.84 % | $ 461 M | USA |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.98 | -0.5 % | $ 8.76 M | USA |
 |
Senseonics Holdings
SENS
|
-1.02 B | $ 5.13 | -22.47 % | $ 214 M | USA |
 |
Soleno Therapeutics
SLNO
|
-431 M | $ 52.86 | 0.08 % | $ 2.69 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.16 | -0.82 % | $ 4.96 M | USA |
 |
Thermo Fisher Scientific
TMO
|
59.2 B | $ 474.62 | -0.94 % | $ 179 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 257.25 | 0.14 % | $ 21.4 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-1.32 B | $ 59.51 | 1.8 % | $ 3.56 B | USA |
 |
Celcuity
CELC
|
-449 M | $ 119.73 | -1.33 % | $ 5.6 B | USA |
 |
Natera
NTRA
|
-1.94 B | $ 206.39 | 0.11 % | $ 20.3 B | USA |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.49 | 1.01 % | $ 2.06 B | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |
 |
Waters Corporation
WAT
|
10.4 B | $ 308.38 | -0.3 % | $ 18.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 194.37 | -0.07 % | $ 21.6 B | USA |
 |
OpGen
OPGN
|
-294 M | - | -16.95 % | $ 1.54 M | USA |